On the stock market since 2001, it operates in the world of health and science. It has 3,256 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 32% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 29% a year on average.
The company sells $2.0B a year; the problem isn’t sales — it’s costs running above that number.
There is $1.7B in the vault; even if every debt were paid off, $1.7B would remain.
A loss of $610.3M against $2.0B in annual sales.
Over the last 12 months, executives reported 251 sells against just 76 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 25% above the average analyst price target.
On our five-subject report card, SGEN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SGEN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.